Skip to content

Kate Owen

Chair of the Board, TransCelerate BioPharma; Head of Global Clinical Development Operations, Bristol Myers Squibb

Kathryn (Kate) Owen is Head of Global Clinical Development Operations within Bristol Myers Squibb. In this role, Kate leads and manages all operations related to the conduct of Bristol Myers Squibb clinical trials – clinical pharmacology studies as well as Phase I through IV. She is also responsible for the data management & data standards, including the tools, systems and processes to support efficient clinical trial execution. The remit of the position includes the oversight of the business systems in support of health economics outcome research (HEOR), investigator sponsored research (ISR), named patient programs (NPP), and data sharing in relation to marketed products. While Kate’s responsibilities focus on global operational execution, she has a passion for assuring the opportunity & the education of clinical trials is afforded broadly.

Kate joined Bristol Myers Squibb in July 2017 from Novo Nordisk, where she served as Vice President of Clinical Trial Management (CTM) and global sponsor of RBM design & implementation. Prior to this, she spent more than eight years in a range of positions of increasing responsibility at Covance after having started her career in the UK in oncology focused biotech. Kate received her undergraduate degree from Royal Holloway, University of London in Biology.